The results of this study showed that compared with the control group, therapeutical effective rate, CD3, CD4, CD4/CD8, and ADRs in the treatment group were all improved, and the incidence of leukopenia and thrombocytopenia after chemotherapy were all reduced, with statistically significant differences. This evidence concerns the gene CD4 and Thrombocytopenia.